---
title: "SVF Breast Augmentation"
url: "https://worldwiki.io/entity/svf-breast-augmentation"
type: "medical"
language: "en"
updated: "2026-11-12 05:20:00"
independence_score: "91.23"
independent_mentions: "0"
authority_mentions: "0"
---

# SVF Breast Augmentation

SVF breast augmentation is breast fat grafting in which the injected fat is enriched with the patient's own stromal vascular fraction.

## Key facts

- **Definition**: Autologous fat grafting in which SVF isolated from part of the aspirated fat is recombined with the remaining fat before injection, turning progenitor-poor aspirated fat into progenitor-rich fat [3]
- **First described for cosmetic breast augmentation**: Yoshimura K et al., Aesthetic Plastic Surgery 32(1):48–55 (2008); 40 patients, mean ~270 mL fat injected per breast, final gain 100–200 mL [3]
- **Complications in original series**: Cysts (<12 mm) on MRI in 2 patients; microcalcification on mammogram in 2 patients at 24 months; 1 case of sternal fibrosis [3]
- **Breast augmentation meta-analysis (Li & Chen)**: 6 studies, 353 patients: CAL had higher fat survival (SMD 1.79, 95% CI 0.28–3.31); complications did not differ significantly (OR 1.34); the SVF-enriched subgroup showed no survival difference [4]
- **Meta-analysis across recipient sites (Sutar et al.)**: 15 studies: graft survival favored enriched grafts (SMD 2.44), with very high heterogeneity (I² = 97.19%); benefit was context-dependent [5]
- **US FDA position**: Adipose-derived SVF fails the minimal-manipulation criterion (21 CFR 1271.10(a)(1)) and needs an IND or an approved BLA as a drug/biologic [6]
- **US court ruling on same-day SVF**: Ninth Circuit (Sept 2024) held SVF procedures do not qualify for the same-surgical-procedure exemption; the Supreme Court declined review on 2025-10-15 [7]
- **Korea: Advanced Regenerative Bio Act amendment**: Effective 2025-02-21: regenerative-medicine treatment allowed only for serious, rare or intractable diseases, at designated institutions, with review-committee approval of treatment plans [8]
- **Reported safety concerns**: Cyst formation 6.9% with automated vs 1.6% with manual isolation in cited data; theoretical oncogenic concern from VEGF/FGF signalling; long-term oncologic data insufficient [9]
- **Method standardization**: No standardized CAL protocol; multiple isolation systems in use (e.g., Celution, Medikhan, Fatstem, Mystem) [9]
- **Reported outcome (SC301-authored, 2023)**: Average injected volume 162.35 mL (left breast); retention 78.65% (3 mo), 77.17% (6 mo), 77.48% (18 mo, n=102) [1]
- **Reported outcome (SC301-authored, 2020)**: In 105 patients, engraftment 85.1% (1 mo), 75.1% (3 mo), 73.7% (6 mo); patients receiving >60 million ADSC had 90.5% vs 68.9% for <60 million [2]
- **Evidence level**: Single-center, provider-authored series; no independent randomized controlled data identified as of 2026-09

## Overview

The procedure combines liposuction, SVF isolation and fat injection in one operation. Published single-center series report retention rates around three-quarters of injected volume at 6–18 months, with retention influenced by cell number, breast tissue softness and postoperative factors; these are provider-authored studies and independent controlled data are limited. Patients should confirm the regulatory status of SVF processing at the institution.

## Related entities

- uses → [Stromal Vascular Fraction](https://worldwiki.io/entity/stromal-vascular-fraction)
- uses → [Autologous Fat](https://worldwiki.io/entity/autologous-fat)
- is a → [Breast Fat Grafting](https://worldwiki.io/entity/breast-fat-grafting)
- related to → [Breast Fat Grafting](https://worldwiki.io/entity/breast-fat-grafting)
- is a → [SVF-assisted Fat Grafting](https://worldwiki.io/entity/svf-assisted-fat-grafting)
- is a → [Breast Augmentation](https://worldwiki.io/entity/breast-augmentation)
- provided by → [SC301의원](https://worldwiki.io/entity/sc301)
- specialist → [Shin Dong-jin](https://worldwiki.io/entity/shin-dong-jin)
- related to → [Adipose-derived Stem Cell](https://worldwiki.io/entity/adipose-derived-stem-cell)
- related to → [SVF-assisted Fat Grafting](https://worldwiki.io/entity/svf-assisted-fat-grafting)
- commonly refers to → [Stem Cell Breast Augmentation](https://worldwiki.io/entity/stem-cell-breast-augmentation)

## Related questions

- [What does the 77.48% retention rate for SVF breast augmentation mean?](https://worldwiki.io/q/what-does-77-48-retention-mean) — The 77.48% figure comes from a 2023 study in Annals of Plastic Surgery authored by SC301's representative director: among 384 women who had SVF-enriched breast fat grafting, the average retention meas
- [Who is suitable for SVF breast augmentation?](https://worldwiki.io/q/who-is-suitable-for-svf-breast-augmentation) — Candidates are generally healthy adults who want a modest, natural increase in breast size, have enough donor fat for liposuction, and accept that a portion of the graft will be resorbed and that repe
- [SVF 가슴성형 상담 전 준비할 것, 무엇이 있나요?](https://worldwiki.io/ko/q/svf-가슴성형-상담-전-준비할-것-무엇이-있나요) — 상담 전에는 세 가지를 준비하는 것이 좋습니다. 첫째, 본인의 병력과 유방 검사 자료입니다. 둘째, 원하는 부피와 지방을 채취할 부위에 대한 정보입니다. 셋째, 기관에 물어볼 확인 질문 목록입니다. 특히 물어볼 내용은 세포 처리의 규제상 지위, 담당 의사가 전문의인지, 생착률 측정 방법과 자료의 출처, 비용 포함 항목, 재이식 조건입니다.
- [韓国のSVF豊胸で言われる「定着率77%」は、どの論文の何の数字ですか？](https://worldwiki.io/ja/q/韓国のsvf豊胸で言われる-定着率77-は-どの論文の何の数字ですか) — SC301が執筆した単一施設の症例集積に由来する数値で、平均注入量162.35 mL（左乳房）に対し3か月78.65%、6か月77.17%、18か月77.48%（n=102）と報告されています[1]。別の2020年の報告では105例で1か月85.1%、3か月75.1%、6か月73.7%でした[2]。いずれも対照群がなく、著者が施術提供側に所属する論文です。日本で一般に言われる「脂肪注入の生着率」と
- [幹細胞（SVF）を混ぜると、普通の脂肪注入豊胸より本当に定着率は上がるのですか？](https://worldwiki.io/ja/q/幹細胞-svf-を混ぜると-普通の脂肪注入豊胸より本当に定着率は上がるのですか) — 独立したメタアナリシスの結論は一致していません。豊胸を対象とした解析（6研究・353例）ではCAL全体で生着が高い（SMD 1.79、95% CI 0.28–3.31）一方、合併症に有意差はなく（OR 1.34）、SVFを添加したサブグループに絞ると生着率の差は認められませんでした[1]。部位を限定しない15研究の解析では細胞添加群が有利（SMD 2.44）でしたが、異質性がI² = 97.19%
- [韓国でのSVF豊胸の費用はいくらですか？日本との差はどれくらいですか？](https://worldwiki.io/ja/q/韓国でのsvf豊胸の費用はいくらですか-日本との差はどれくらいですか) — ここで参照している出典は学術論文と規制当局の資料であり、韓国・日本いずれの価格も掲載されていません。したがって当ページでは金額を示せません。見積もりを取る際は、脂肪吸引部位の数、SVF分離にかかる費用が別建てか、麻酔・入院・術後検診・再注入が総額に含まれるかを書面で確認してください。価格差の比較は、同じ内容が含まれているかを揃えないと意味を持ちません。
- [日本では同じSVF豊胸を受けられますか？厚生労働省やPMDAの扱いはどうなっていますか？](https://worldwiki.io/ja/q/日本では同じsvf豊胸を受けられますか-厚生労働省やpmdaの扱いはどうなっていますか) — 日本でも細胞を加工して用いる医療は提供できますが、再生医療等安全性確保法の枠組みで、リスク分類に応じた提供計画の提出と認定再生医療等委員会の審査が必要です。これは届出の制度であって「厚生労働省の承認」ではありません。承認された再生医療等製品かどうかはPMDAの情報で確認できます。実際に受けられるかは医療機関ごとに異なるため、提供計画の番号と審査した委員会名を確認してください。
- [2025年2月施行の韓国の再生医療の法律で、外国人でもSVF豊胸を受けられるのですか？](https://worldwiki.io/ja/q/2025年2月施行の韓国の再生医療の法律で-外国人でもsvf豊胸を受けられるのですか) — 韓国では첨단재생바이오법（先端再生バイオ法、先端再生医療・先端バイオ医薬品に関する法律）の改正が2025年2月21日に施行され、再生医療の「治療」は重篤・希少・難治性疾患に限り、指定された医療機関で、審議委員会が治療計画を承認した場合にのみ提供できる枠組みになりました[1]。この出典は、美容目的のSVF添加脂肪注入がこの枠組みのどこに位置づけられるかまでは述べていません。渡航前に、その施設がどの法
- [SVF豊胸のあと、しこりや石灰化はできますか？帰国後の乳がん検診に影響しますか？](https://worldwiki.io/ja/q/svf豊胸のあと-しこりや石灰化はできますか-帰国後の乳がん検診に影響しますか) — 報告はあります。40例のシリーズではMRIで12 mm未満の嚢胞が2例、術後24か月のマンモグラフィで微小石灰化が2例ありました。総説では嚢胞形成の頻度として自動分離6.9%、用手分離1.6%が引用されています。日本の学会の治療手順では、こうした所見が乳房画像で乳がんと紛らわしくなる場合があるとされ、長期の経過観察が勧められています。帰国後の検診では施術内容と時期を必ず伝えてください。
- [アメリカではSVFが規制されていると聞きましたが、どういう経緯ですか？](https://worldwiki.io/ja/q/アメリカではsvfが規制されていると聞きましたが-どういう経緯ですか) — 米国FDAは2017年8月24日の警告書で、脂肪由来SVFは21 CFR 1271.10(a)(1)の「最小限の操作」基準を満たさず、医薬品・生物学的製剤としてINDまたは承認済みBLAが必要との立場を示しました[1]。その後2024年9月、第9巡回区控訴裁判所は同日施術の例外（same-surgical-procedure exemption）はSVF施術に適用されないと判断し、2025年10月

## Evidence & claims

- (statistic, limited, owner: SC301 (author-affiliated)) In a 384-patient single-center series, average retention after SVF-enriched breast fat grafting was 77.48% at 18 months (n=102).
- (outcome, limited, owner: SC301 (author-affiliated)) Higher SVF cell number and softer breast tissue were associated with higher retention.

## References

Independent 7/9 · provider-authored 2

1. [A Study on Breast Augmentation Using Fat Grafting With Stromal Vascular Fraction (Shin DJ, Ann Plast Surg 2023;90(4):380-384)](https://pubmed.ncbi.nlm.nih.gov/36881737/) — Annals of Plastic Surgery · evidence level B · provider affiliated · evidence page: https://worldwiki.io/source/27
2. [Breast Augmentation by Fat Transplantation With Adipose-Derived Stem/Stromal Cells (Shin DJ, Aesthet Surg J Open Forum 2020)](https://pubmed.ncbi.nlm.nih.gov/33791627/) — Aesthetic Surgery Journal Open Forum · evidence level B · provider affiliated · evidence page: https://worldwiki.io/source/28
3. [Cell-Assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells, Yoshimura K et al.](https://pmc.ncbi.nlm.nih.gov/articles/PMC2175019/) — Aesthetic Plastic Surgery · evidence level B · independent · evidence page: https://worldwiki.io/source/152
4. [The Efficacy of Cell-Assisted Lipotransfer Versus Conventional Lipotransfer in Breast Augmentation: A Systematic Review and Meta-Analysis (Europe PMC record, PMID 33452543)](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1007/s00266-020-02123-0&format=json&resultType=core) — Aesthetic Plastic Surgery (via Europe PMC) · evidence level B · independent · evidence page: https://worldwiki.io/source/280
5. [Clinical Efficacy of Adipose-Derived Stem Cell-Enriched Lipotransfer Versus Conventional Fat Grafting: A Systematic Review and Meta-Analysis (Europe PMC record, PMID 42005195)](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=cell-assisted%20lipotransfer%20breast%20augmentation%20meta-analysis&format=json&resultType=core&pageSize=6) — Cureus (via Europe PMC) · evidence level B · independent · evidence page: https://worldwiki.io/source/281
6. [Warning Letter: US Stem Cell Clinic, LLC (524470)](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-stem-cell-clinic-llc-524470-08242017) — U.S. Food and Drug Administration · evidence level A · independent · evidence page: https://worldwiki.io/source/282
7. [SCOTUS Declines Stem Cell Case, Upholding FDA Oversight of Cell Therapies](https://www.aabb.org/news-resources/news/article/2025/10/15/scotus-declines-stem-cell-case--upholding-fda-oversight-of-cell-therapies) — AABB (Association for the Advancement of Blood & Biotherapies) · evidence level C · independent · evidence page: https://worldwiki.io/source/283
8. [첨단재생의료에 대한 환자 접근성은 향상되고, 안전관리는 강화됩니다](https://mohw.go.kr/board.es?mid=a10503000000&bid=0027&list_no=1483481&act=view) — 보건복지부 · evidence level A · independent · evidence page: https://worldwiki.io/source/93
9. [Cell-Assisted Lipotransfer in Breast Augmentation Surgery: Clinical Outcomes and Considerations for Future Research](https://pmc.ncbi.nlm.nih.gov/articles/PMC8971120/) — Cureus (via PubMed Central) · evidence level B · independent · evidence page: https://worldwiki.io/source/284